Using a treat-to-target approach , open-label conventional synthetic disease-modifying antirheumatic drugs ( csDMARDs ) , other than MTX , were added from week @ if Disease Activity Score in @ joints based on erythrocyte sedimentation rate ( DAS@-ESR ) > @ .